KYKentaro Yasuda

Kentaro Yasuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kentaro Yasuda has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy

    by Satoshi Shigeno, Takahiro Kodama, Kazuhiro Murai, Emi Sometani, Kentaro Yasuda, Yuki Tahata, Akira Nishio, Satoshi Tanaka, Masanori Miyazaki, Kazuyoshi Ohkawa, et al.

    Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.